Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

The recent identification of ion-channel subtypes and ion transporters on the myelinated axon has allowed the characterization of changes in their distribution and density after demyelination.

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...

The destruction of myelin sheaths—demyelination—can occur in the context of brain inflammation and can lead to cognitive, movement and other neurological problems. The phenomenon is seen in ...

New research findings dispel the dogma that slower hyponatremia correction is better. Faster correction of severe hyponatremia is associated with a lower death rate, investigators report.